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Multiplication of certain adenoviruses is known to be accompanied by forma- 
tion of several factors which possess virus-specific antigens and which are dis- 
tinct from the infectious particles; these are the complement-fixing antigen or 
antigens  (1),  and  the cell-detaching factor  (2),  which is presumably identical 
with the early cytopathogenicity factor (3, 4), and the C  antigen (5). In addi- 
tion, preliminary evidence (6) has been presented which indicates that infection 
of tissue cultures with several of the adenoviruses results in formation of a  fac- 
tor demonstrable by its capacity to reduce the agglutinability of human group 
O erythrocytes by 3 of the 5 adenoviruses which hemagglutinate these cells (7). 
The purpose of this report is to present in greater detail the biologic, serologic, 
and chemical characteristics of the erythrocyte receptor-modifying factor. 
Materials and Methods 
Tissue Cultures.--HeLa and  Hep.  2  tube cultures were  obtained from  Microbiological 
Associates, Inc., Bethesda, Maryland. The cultures were handled and maintained as previously 
described (8). The maintenance medium for HeLa cell cultures consisted of 70 parts medium 
199  (9),  25 parts tryptose phosphate broth, and 5 parts chicken  serum.  The maintenance 
medium for Hep. 2 cell cultures consisted of 95 parts Eagle's basal medium (10) and 5 parts 
chicken serum. The chicken serum was heated at 56°C for 30 minutes before use. In addition, 
the media contained penicillin,  streptomycin, and nystatin in a  final concentration of 250 
units, 250 t~g, and 50 units per ml, respectively. Cultures received a fresh fluid change  once 
weekly. 
Viruses.--The piototype adenovirus strains of types 1 through  18  (11) were used; type 
BAR-2  was received from Dr. Leon Rosen  (7). For the preparation of adenovirus stocks, 
tube cultures of HeLa cells were inoculated with 0.15 ml of a virus dilution which produced 
complete cytopathic effects within 2 to 4 days; 2 days after cytopathic effects were complete, 
the cultures were frozen,  later thawed, and clarified by centrifugation at  1500 P,  PM for 15 
minutes.  Flui~ts were then stored in glass vials and frozen at -20°C until used. Uninoculated 
HeLa cell cultures were processed in the same manner for use as control fluids. 
* Material taken from thesis submitted to the Graduate School of Georgetown University 
in partial fulfillment of requirements for the degree of Doctor of Philosophy. 
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Infectivity  Titrations.--Titrations  for infectivity were done by inoculating 1 ml  of serial 
10-fold dilutions of virus into each of 2 Hep. 2 cultures from which the maintenance medium 
had been previously removed. The cultures were incubated at 37°C in a stationary horizontal 
position and observed as long as uninoculated control cultures remained in satisfactory condi- 
tion.  Cultures  developing any  definite characteristic cytopathic changes were considered 
positive; titers were calculated according to the method of Reed and Muench (12). 
Erythrocyte  Suspensions.--Human  group O  red cells  were obtained from 2  donors. The 
blood was placed in Alsever's solution, and the erythrocytes were separated and washed by 
three cycles of centrifugation at 2000 Rv~ for 5 minutes with resuspension in 3 volumes of 
saline solution (0.85 per cent NaC1).  After the final  centrifugation, the packed cells  were 
resuspended in Alsever's solution and stored at 4°C. Before use, the red cells were washed once 
with 3 volumes of saline. Fresh human cells were collected every 10 days. 
Hemagglutination  Tests.--Tests were done in 12 X  75 mm tubes; serial 2-fold virus dilutions 
were prepared in physiologic saline, using a fresh pipette for each dilution. 0.2 ml of a  1 per 
cent erythrocyte suspensionwasaddedto0.8  ml of virus dilution, and the tubes were thoroughly 
shaken. Tests with human erythrocytes were held at 37°C for 60 to 90 minutes. The highest 
virus dilution showing approximately a  50 per cent pattern of sedimentation (13) was the 
end point of the titration. 
Erythrocyte  Receptor Modification  Test.--In  the standard test for demonstrating erythro- 
cyte receptor modification 0.25  ml of packed human group O erythrocytes were added to 4 
ml of undiluted virus and HeLa control fluids and thoroughly mixed. The mixtures were held 
at 22°C for 2 hours and the tubes shaken every 15 minutes during the incubation period. The 
red cells then were separated by centrifugation at 1500 RPM for 5 minutes, washed in 2 saline 
changes of 7 ml each, and finally resuspended as a  1 per cent suspension in saline. These 
treated cell suspensions were used to determine hemagglutination titers of adenovirus types 
10,  13,  and  BAR-2  (test viruses). A  test was considered positive for erythrocyte receptor 
modification if there was an 8-fold or greater reduction in titer of test virus hemagglutinin 
with the virus-treated ceils as compared with the titer obtained with  HeLa  control fluid- 
treated cells. 
Tests for Inhibition of Erythrocyte Receptor-Modifying  Activity  by Rabbit  Antisera.--Rabbit 
immune sera for adenoviruses and HeLa control fluid  were prepared as described by Rowe 
et al. (1). The sera were adsorbed with human group O erythroeytes before use by adding 0.1 
ml of packed erythrocytes to 2 ml of undiluted serum. The mixture was kept  at 4°C for 18 
hours, and the red cells were removed by centrifugation at 1500 ~PM for  20 minutes. Before 
use, a 1:20 dilution of the adsorbed serum was tested for the presence of red cell agglutinins; 
on occasion,  it was necessary to repeat the adsorption procedure. 
The inhibition test was done as follows: 0.2  ml of undiluted serum  (inactivated at  56°C 
for 30 minutes) was added to 4 ml of a virus dilution containing 1.5 logs of erythrocyte recep- 
tor-modifying activity.  Controls for each test consisted of a  titration  of  the  erythrocytc 
receptor-modifying  activity of each virus fluid, cell treatment with mixtures of HeLa control 
fluid and each of the antisera used in the test, and cell treatment with mixtures of each virus 
and HeLa control fluid rabbit antiserum. Mter the mixtures were incubated at 37°C for 60 
minutes, 0.25 ml of packed erythrocytes were added. Resuspended red cell suspensions were 
prepared and  assayed  as  described above.  Complete  inhibition  of  erythrocyte  receptor- 
modifying activity by serum was considered positive neutralization. 
EXPERIMENTS  AND  RESULTS 
General Characteristics of the Erythrocyte Receptor Modification  Reaction 
Prevalence of Erythroeyte Receptor-Modifying Activity Among A denoviruses.-- 
Table I  presents  the  results  of experiments to  determine the  prevalence of J.  A.  KASEL,  W.  P.  ROWE,  AND  J.  L.  NEMES  719 
erythrocyte receptor-modifying activity among the adenovirus serotypes which 
lack the capacity to agglutinate human group O erythrocytes. Also, a prepara- 
tion of type 10, from which the hemagglutinin had been removed by adsorption 
with human O erythrocytes, was tested. In each experiment, a type 1 or type 15 
suspension  was included  as  a  positive control,  and  the  results  of the  repeat 
assays are given in the table. Only adenovirus type 1, 2, 4, and 15 suspensions 
TABLE I 
A gglutinability of Human Group 0 Erythrocytes Pretreated with Adenoviruses 
Hemagglutination fiter with HCF*-treated erythrocytes 
Hemagglutination titer with virus-trested erythrocytes 
Treating virus 
Ad.~: 8  Ad. 9  Ad. 10  Ad. 13  Ad. BAR-2 
Ad. 1 
Ad. 2 
Ad. 3 
Ad. 4 
Ad. 5 
Ad. 6 
Ad. 7 
Ad. 7a 
Ad. 10§ 
Ad. 11 
Ad. 12 
Ad. 14 
Ad. 15 
Ad. 16 
Ad. 17 
Ad. 18 
2; 2; 1; 1; 1  1; 2; 2; 2; 1  16;64;64; 
32;64 
32 
1 
16 
16; 32; 32; 
32; 32 
32 
1 
16 
2  1 
1  1 
2  1 
1  2 
1  1 
1  1 
1  1 
1/2  i 
1;2  I; 
1  1 
1  1 
1  1 
1 
1 
1 
1 
16; 32 
1 
1 
1 
1 
2 
1 
2 
NOll 
1 
1 
2 
8;8 
1 
1 
1 
16; 16; 32; 
16; 32 
32 
1 
8 
1 
l 
1 
1 
1 
1/2 
1 
1 
16; 32 
1 
! 
1 
* HeLa control fluid. 
:~ Adenovirus. 
§ Suspension adsorbed 5 times with human O erythrocytes to remove hemagglutinin. 
[I Not done. 
demonstrated the property of markedly reducing the agglutinability of erythro- 
cytes for type 10,  13, and BAR-2 hemagglutinins. The reduction in hemagglu- 
tinin  titer of the  test viruses varied from 8-  to 64-fold, the greater reduction 
being produced  by type  1 and  2  virus fluids.  In no instance  were significant 
decreases observed for types 8 and 9. 
To determine if production or lack of production of the erythrocyte receptor- 
modifying factor was characteristic for the adenovirus serotypes, a  number of 
additional  strains of types 1,  2,  3,  and 5  were tested.  Freshly isolated strains 
were obtained from Dr.  Robert Parrott  of the  Children's  Hospital Research 
Center,  Washington, D.  C.; these consisted of 5 strains of type 1, 5 strains of 720  ERYTHROCYTE  RECEPTOR  MODIFYING  FACTOR 
type 2, 4 strains of type 3, and 4 strains of type 5, all in second or third passage 
in HeLa cells. All of the type 1 and 2 strains, and none of the type 3 and 5 strains 
produced modification of  erythrocyte receptors.  However,  all  of  the  type  5 
strains resulted in a 2-fold reduction of test virus hemagglutinin. 
Different lots of HeLa cultures  infected with  adenoviruses produced rela- 
tively constant titers of erythrocyte receptor-modifying activity for each sero- 
type. The titers of type 1 and 2 suspensions were 1:100 to 1:320, type 4 titers 
were usually 1 : 32, and type 15 titers were from 1 : 10 to 1 : 32. 
Dose-Response Relationship.--The  pattern of relationship of dose of treating 
virus  (adenovirus type  1)  to the degree of receptor modification is  shown in 
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FIo. 1.  Relation of dose of treating virus to HA titers obtained with test viruses. 
Fig. 1. Through a portion of the dilution range the relation was approximately 
linear, but a point was reached at which increase in dose of treating virus pro- 
duced no further decline in agglutinability. This pattern was also seen with the 
other  adenovirus  types  which  produced  the  erythrocyte receptor-modifying 
factor; only rarely was agglutination prevented completely. In contrast, treat- 
ment of human O cells with the receptor-destroying enzyme (RDE) of Vibrio 
cholerae rendered them inagglutinable by the larger doses of adenovirus types 
10, 13, and BAR-2. 
The slope of the linear portion of the curve varied with different batches of 
red  cells,  but  tended  to  be constant  with  a  given batch;  the  variation  was 
primarily steeper slopes than those shown in Fig.  1. In general, the various al- 
terations of experimental conditions and treatments of the erythrocyte recep- 
tor-modifying factor reported here, did not alter the form of the dose-response 
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Effect of Temperature and Time on Erythrocyte Receptor Modification.--Since 
the initial  studies  of adenovims receptor modification were carried out with 
treatment of red cells at 22°C for 2 hours, this exposure was used as the standard 
method in subsequent work. To determine the effect of variation in temperature 
and duration of red cell treatment, experiments were done in which one factor 
was varied and the other maintained  constant as in  the standard  treatment 
conditions. 
Table II presents  the  results  of an  experiment which tested the  effect of 
temperature during a constant incubation period on the erythrocyte receptor- 
modifying activity of adenovirus type 1 and 15 suspensions. 
Erythrocytes were added to triplicate sets of virus dilutions and undiluted HeLa control 
fluid, and the sets of mixtures were placed at 2°C, 22°C, and 37°C respectively;  test  fluids 
TABLE  II 
Effect of Temperature  on  the  Degree of Erythrocyte Receptor  Modification  During a  Constant 
Time Period 
Treating virus 
Ad.  1 
Ad.  15 
Highest dilution of treating virus producing > 8-fold reduction of hemagglutination 
titer of test viruses Ad. 10 and Ad. 13 
Mixtures held at 2°C 
Ad. lO  Ad. 13 
101.5  101.5 
10o.5  100 
Mixtures held at 22°C 
Ad. I0  Ad. 13 
102.5  10~.5 
101.~  101.0 
Mixtures held at 37°C 
Ad. 10  Ad. 13 
103.0  108.0 
>101.5  101.5 
and red cells had been brought to corresponding temperatures before mixing. Mter incubating 
for  2  hours,  the  mixtures were  chilled  and  erythrocyte  suspensions were  prepared  under 
temperature conditions not exceeding 4°C. 
As  shown  in  Table II,  erythrocyte  receptor-modifying activity  increased 
with  temperature  of  the  virus-red  cell  mixture;  the  erythrocyte receptor- 
modifying titers obtained were increased approximately 30-fold over the tem- 
perature  extremes. 
The following experiment was  done to  determine the effect of length of ex- 
posure on the degree of receptor modification at a constant temperature. 
Red cells were added to replicate sets of adenovirus type 1 dilutions as well as to undiluted 
HeLa control fluid and held at 22°C; the materials were at 22°C at the time of  admixture. 
At various time intervals, a  set of the treatment mixtures was placed in a  chilled centrifuge 
head and centrifuged at  1500 m,~ for 3  minutes in a  refrigerated  centrifuge; suspensions of 
washed erythrocytes were then prepared.  The results of this experiment are shown in Table 
III. 
After only 1 minute's exposure at 22°C  the 10  -1 dilution of adenovirus type 1 
suspension had reduced the agglutinability of the cells by a significant amount. 722  ERYTHROCYTE  RECEPTOR-MODIFYING  FACTOR 
Contact  for  2  hours  was  necessary for  the  10  -2.5  dilution  to  effect  significant 
receptor modification. 
Erythrocyte Receptor-Modifying Activity Following Reaction with Red Cells.- 
To  determine  if  the  erythrocyte  receptor-modifying  factor  in  adenovirus  suspensions 
adsorbed  irreversibly to  red  cell  receptor  sites,  erythrocyte  receptor-modifying  titers  of 
adenovirus suspensions were determined following successive treatment with fresh erythro- 
TABLE  III 
Rate of Erflhrocyte Receptor Modification by Adenovirus Type l  Suspension at 22°C 
Length of treatment  Titer of erythrocyte receptor-modifying  activity* 
mln 
1 
5 
10 
20 
60 
120 
101,0 
101.5 
101.5 
10~.0 
102.o 
102.5 
* Highest dilution of the Ad.  1 suspension which produced  >_ 8-fold decrease in aggluti- 
nability of the erythrocytes by Ad.  10 test virus. 
TABLE  IV 
Erythrocyte Receptor-Modifying Activity of Adenovirus Type 1 and 15 Suspensions Following 
Successive Reactions with Human Erythrocytes 
Erythrocyte treatment 
Ad.  1, initial suspension ..................... 
Ad. 1, suspension after 5 cycles of reaction with 
erythrocytes ............................ 
Ad.  15, initial suspension ................... 
Ad.  15, after 6 cycles of reaction with erythro- 
cytes ................................... 
Titers of erythrocyte receptor-modifying  activity 
as determined  with three test viruses 
Ad. 10  Ad. 13 
10~.5  102.5 
102.5  102.~ 
101.5  lOX.~ 
101.s  101-5 
Ad. BAR-2 
10  2.5 
102.5 
101.5 
101.5 
cytes.  1 volume of packed red cells was added to 16 volumes of undiluted adenovirus types 
1 and 15 and HeLa control fluids, respectively, and the mixtures held at 22°C for 2 hours. 
Erythrocytes were separated by centrifugation and discarded, and the supernatant fluid was 
then added to fresh erythrocytes. This procedure was repeated 5 times with adenovirus type 
1 and 6 times with type  15 suspensions. Erythrocyte receptor--modifying activity of these 
suspensions and corresponding suspensions which had not been subjected to cyclic treatment 
with red cells were assayed in the erythrocyte receptor modification titration test (Table IV). 
The  adenovirus  erythrocyte  receptor-modifying  factor  was  not  irreversibly 
attached  to the erythrocytes,  since  the  virus  fluids  after  successive  exposures 
with red cells had activity equal to the initial suspensions. j.  A.  KASEL,  W.  P.  ROWE,  AND  J.  L.  NEMES  723 
Adsorption  of Test  Virus to Erythrocyte  Receptor-Modifying  Factor-Treated 
Cells.--To investigate whether inagglutinability of virus-treated erythrocytes 
was due to the modification of receptors with consequent lack of adsorption of 
hemagglutinin or due to failure of red cells with attached virus to form char- 
acteristic agglutination patterns,  experiments were done to determine if test 
virus hemagglutinin adsorbed to the treated cells. 
1 ml of packed group 0 erythrocytes was added to tubes containing 16 ml of saline, undi- 
luted HeLa control fluid, and adenovirus type 1, respectively. Mter incubation at 22°C for 2 
hours, red cells were washed twice with saline. 2 ml of undiluted adenovirus type 10 was then 
added to each tube containing 0.5 ml of packed treated red cells. These mixtures were held 
at 22°C for 30  minutes, and then centrifuged at  1500 R•M  for 5 minutes. The supernatant 
fluids were assayed for unadsorbed type 10 by determining the hemagglutinin titers against 
fresh untreated erythrocytes. The results of this experiment are shown in Table V. 
TABLE V 
Hemagglutination Titer of Adenoz4ru, Type 10 Suspension Following  Adsorption with Treated 
Erythrocytes 
Treatment of Ad. 10 suspension 
Untreated ............................................. 
Adsorbed with saline-treated RBC:~ ....................... 
Adsorbed with HCF-treated RBC ........................ 
Adsorbed with Ad. 1-treated RBC ....................... 
Hemagglufination fiter*  of 
adsorbed Ad. 10 suspensions 
128 
8 
8 
64 
* Reciprocal of titer obtained with untreated erythrocytes. 
:~ Red blood cells. 
The type 10 virus hemagglutinin adsorbed far less  efficiently to the adeno- 
virus-treated cells than to either the saline or HeLa control fluid-treated ceils. 
Effect of the Erythrocyte Receptor-Modifying  Factor on Red Cell Antigens and 
Human  A  and A B  Erythrocytes.--Group  0  Rh-positive erythrocytes  which 
were pretreated in the standard manner with physiologic saline, HeLa control 
fluid, and an adenovirus type 1 suspension were tested for phenotype charac- 
teristics by Dr. W.  Bronson from the National Institutes of Health,  Clinical 
Center Blood Bank. The 3 samples gave a positive reaction for M, N, V, P, D, 
c, e, Kp  b, k, JK  ~, and Le  b antigens, and were negative for S, C w, C, E, K, Kp  ~, 
Fy% JK  b, V, and Le  A  antigens. All negative results were checked microscopic- 
ally. It was noted, however, that adenovirus type 1-treated cells exhibited a 
stronger reaction than the saline and HeLa control fluid-treated cells with  c 
and e antisera. 
Human erythrocytes from donors with blood group typings A and AB treated 
with an adenovirus type 1 suspension exhibited the same decrease in agglutin- 
ability against the test viruses as did group O erythrocytes. 724  ERYTHROCYTE  RECEPTOR-MODIFYING  FACTOR 
Physicochemical  Studies of the Erythrocyte  Receptor-Modifying Factor 
Dialysis.--Suspensions of  adenovirus  types  1,  2,  and  15  were  dialyzed  against  several 
changes of continuously stirred 1 ~  tris buffer solution or distilled water at 4°C for 18 hours. 
The erythrocyte receptor-modifying factor of the adenovirus suspensions was always retained 
in the non-dialyzable portion. 
Iteat.--Erythrocyte receptor-modifying activity of adenovirus type 1  and  2  suspensions 
was not affected by heating in sealed and submerged ampules at 70°C for 30 minutes. Heating 
at 80°C for 30 minutes, however, reduced the erythrocyte receptor-modifying  titer  by  0.5 
log10, and heating at 90°C for 30 minutes or 100°C  for 10 minutes completely destroyed  the 
erythrocyte receptor-modifying activity. 
Ultraviolet Irradiation.--Tests for sensitivity to ultraviolet irradiation were done by Dr. 
Samuel Baron of the Division of Biologic Standards of  the National Institutes of  Health. 
Undiluted type 1 and 2 adenovirus suspensions and HeLa control fluid in 10 ml aliquots were 
placed in 90 mm diameter Petri dishes and placed on a rotary shaker below a  15 watt  General 
Electric germicidal lamp for 30 minutes. The radiation intensity  was  120  gw  per  cm  2 as 
measured with an  Archer radiation meter.  (Archer-Daniels-Midland Co.,  Cleveland).  The 
erythrocyte receptor modification titers of the irradiated virus suspensions were identical to 
the non-irradiated virus suspensions. 
Ether.--An 18 hour exposure at 4°C and extraction of adenovirus type i  and 2 suspensions 
with 50 per cent diethyl ether did not affect the erythrocyte receptor--modifying activity of 
these suspensions. 
Enzymes.--Crystalline ribonuclease  (RNAase)  and  desoxyribonuclease  (DNAase)  were 
received through the courtesy of Dr. Hilton B. Levy from the National Institutes of Health. 
Enzyme solutions containing 1 mg/ml were prepared with 1 M tris buffer, pH 7.8.  1 volume 
of enzyme solution was added to 10 volumes of undiluted HeLa control fluid and adenovirus 
type  1 and  15  fluids.  Control preparations consisted of fluids treated with buffer solution. 
Prior to the addition of RNAase,  test materials were dialyzed overnight in the cold and ad- 
justed to pH  7.8.  The materials used for DNAase treatment were adjusted  to pH  7.8 and 
contained in addition  to  the enzyme,  0.03  M MgCI~. Following incubation at  37°C  for  60 
minutes, the materials were kept at 4°C until assayed. The erythrocyte receptor modification 
titers of the virus suspensions treated with enzymes were identical to those of the untreated 
suspensions. 
Type 1 and 2 adenovirus suspensions and HeLa control fluid which were prepared in HeLa 
cell cultures containing protein-free medium 199 were treated with trypsin (Armour and Co., 
Chicago)  and  chymotrypsin  (Worthington Biochemicals  Corp.,  Harrison,  New  Jersey).  A 
1 per cent enzyme solution was prepared in 0.02 ~  phosphate buffer, pH  7.8.  1 volume of 
enzyme solution was added  to 3 volumes of HeLa control fluid and virus fluids, which had 
been adjusted to pH 7.8.  Virus and HeLa control fluids mixed with buffer were used as con- 
trois. Mter incubation of the mixtures at 37°C for 60 minutes, 1 volume of a  1 per cent soy- 
bean trypsin inhibitor  (Nutritional Biochemicals Corp.,  Cleveland)  prepared  in phosphate 
buffer was added to the enzyme-treated and control fluids.  When assayed, the virus suspen- 
sions treated with trypsin and chymotrypsin gave erythrocyte receptor  modification titers 
comparable to those of the non-enzyme-treated virus fluids. 
Serum Inhibition 
Inhibition  of  the  erythrocyte  receptor-modifying  factor  of  adenovirus  sus- 
pensions by rabbit antiserum was demonstrated  in neutralization tests done as 
described  under  Materials  and  Methods.  The  results  of  representative  tests 
are  shown  in Table  VI.  Type-specific  neutralization  was  observed  since  there J.  A.  KASEL,  W.  P.  ROWE~ AND  J.  L.  NEM.ES  725 
was no reduction in test virus hemagglutinin titers in tests of erythrocytes which 
were pretreated  with homologous virus-serum mixtures.  In contrast,  test virus 
TABLE  VI 
Effect of Rabbit A ntisera on Erythrocyte Receptor Modification by A denoviruses 
Erythrocytes treated with mixture of  Hemagglutination titer* of test virus (type 10) against 
treated erythrocytes 
Treating virus  HeLa con-  Ad. 15 
trol fluid  Rabbit antiserum (1 : 1) 
Normal rabbit serum ............... 
HeLa control fluid-immunized ...... 
Ad.  1-immunized ................. 
Ad. 2-immunized .................. 
Ad. 4-immunized ................. 
Ad.  1  5-immunized ................ 
256 
256 
256 
256 
256 
256 
Ad. 1 
16 
16 
256 
8 
16 
16 
Ad. 2 
16 
16 
16 
256 
8 
16 
Ad. 4 
8 
8 
8 
8 
256 
8 
16 
16 
16 
16 
16 
256 
* Reciprocal of dilution. 
TABLE  VII 
Separation  of Erythrocyte  Receptor-Modifying  Factor from  Infectious  Virus  in  Adenovirus 
Suspensions  by Ultracentrifugation 
Material used to treat human erythrocytes 
Ad.  1, initial suspension ................ 
Ad.  1, supernate fraction, S-3 ........... 
Ad.  1, pellet fraction, P-3 .............. 
Ad. 2, initial suspension ................ 
Ad. 2, supernate fraction, S-3 ........... 
Ad. 2, pellet fraction, P-3 .............. 
Ad.  15, initial suspension ............... 
Ad. 15, supernate fraction, S-3 .......... 
Ad. 15, pellet fraction, P-3 ............. 
Titer of erythrocyte receptor-modifying 
activity as determined with 
three test viruses 
Ad. 10 
102.5 
102.5 
<102.5 
102.5 
102.0 
<10o5 
101.0 
101.0 
<10  o 
Ad. 13  Ad. BAR-2 
102.5  102.0 
102.5  102.5 
<10o.5  <10o.5 
102.6  102.5 
102.5  102.5 
<102 .5  <100-6 
10  1.0  10o.5 
10  0.5  102 
< 10  °  < 10  ° 
Infectivity 
titer* 
TCDso]ml 
10  7.0 
102.5 
104.° 
102.° 
102.5 
105.0 
10  4  .5 
104.s 
102.5 
* Titer calculated after 25 days in Hep. 2 cultures. 
hemagglutinin  titers  were  significantly  reduced  (8-fold  or  greater)  in  tests 
against erythrocytes pretreated with heterologous virus-serum mixtures. 
Separation  of Erythrocyte Receptor-Modifying  Factor from  Infectious  Virus 
In a  previous report (6) evidence was presented which indicated that erythro- 
cyte receptor-modifying  activity of an adenovirus suspension was  not a  func- 
tion of the infectious virus particle, in that  the bulk of the infectivity of a  type 726  ERYTHROCYTE  RECEPTOR-MODIFYING  FACTOR 
15  adenovirus  suspension  could  be removed by adsorption  with  rat  erythro- 
cytes, without decreasing the erythrocyte receptor-modifying titer. To further 
establish the distinctness of the two factors, separation by ultracentrifugation 
was attempted. 
Three tubes containing 11.6 ml of infectious tissue culture fluid were placed in a  Spinco 
No. 40 rotor head and centrifuged in a Spinco model L ultracentrifuge at 40,000 RP~ (average 
105,400 g) for 90 minutes. Following centrifugation, the uppermost 8 ml of fluid was removed 
from each tube and pooled, the remaining fluid discarded, and the pellets resuspended in 11.6 
ml of saline and pooled. This procedure was repeated through three cycles of centrifugation; 
the final pooled supernatant fluids were designated as S-3 and the final pooled resuspended 
pellets as P-3. Adenovirus type 1, 2, and  15 fractions were prepared in this manner. These 
fractions and initial virus fluids were assayed for infectivity and erythrocyte receptor-modi- 
fying titers. The results of these experiments  are shown in Table VII. 
Erythrocyte  receptor-modifying activity  was  found  only in  S-3  fractions, 
while the pellet fractions contained the bulk of the recovered virus. Thus, the 
centrifugation studies confirmed that the erythrocyte receptor-modifying fac- 
tor was separable from infectious virus and also indicated  that it was smaller 
than  the virus particle. 
DISCUSSION 
The experiments presented here demonstrated that adenovirus type 1, 2,  4, 
and  15  infectious  tissue  culture  fluids  contained  a  non-dialyzable  factor 
separable from and smaller than the virus particle which was capable of modi- 
fying  human  erythrocyte receptors  for  type  10,  13,  and  BAR-2  adenovirus 
hemagglutinins.  It  was  somewhat  puzzling  that  the  erythrocyte-modifying 
factor was found only with these types, and not with other adenovirus types 
closely related in many biological attributes to the types producing the factor. 
It is possible that the failure to demonstrate the activity in the other adenovirus 
suspensions is due  to differences in the experimental conditions  necessary for 
demonstrating the  activity,  or to differences in  the  ease of extraction of the 
factor from infected tissue culture cells. 
Both ultracentrifugation  and red cell adsorption  studies indicated  that  the 
erythrocyte receptor-modifying factor was distinct  from the  infectious virus 
particle,  but  differentiation  from  or  identification  with  other  non-infectious 
adenovirus  antigens  is  not  yet possible.  The  type  specificity of its  antigenic 
structure as indicated by the serum inhibition tests, and the fact that the factor 
was produced by only a few adenovirus types, makes it quite unlikely that the 
erythrocyte receptor modifying-factor is  the  soluble complement-fixing anti- 
gen.  Also,  the  resistance  of  the  erythrocyte  receptor-modifying  activity  to 
trypsin treatment serves effectively to differentiate it from the cell-detaching 
factor, early cytopathogenicity factor, or B  antigen  (5). The  C  antigen  (5)  is 
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amounts by adenovirus  type 5, whereas, the erythrocyte receptor-modifying 
factor is not. It is possible that the erythrocyte receptor-modifying  factor is the 
C antigen, but in the case of type 5, devoid of the biologic activity. 
Attempts to identify the chemical nature of the erythrocyte receptor-modi- 
fying factor by demonstrating inactivation by specific chemical and physical 
means were unsuccessful since the activity remained intact after exposure to 
desoxyribonuclease,  ribonuclease,  trypsin,  chymotrypsin,  ether,  and  ultra- 
violet  irradiation.  Perhaps  enzyme  inactivation  tests  with  highly purified 
erythrocyte receptor-modifying factor, free of potential inhibitors,  should such 
become  available,  would  give  positive  results.  Since the factor is  a  macro- 
molecular, heat-labile  substance  which reacts with immune serum, and which 
behaves  in some respects  like an enzyme, it is suggested that it is a protein 
which is resistant to trypsin and chymotrypsin digestion. 
The mechanism  of action of the erythrocyte receptor-modifying factor is 
not known, but certain biologic data suggest that the reaction may be of an 
enzymatic nature. The degree of receptor  destruction was a function of tem- 
perature  and  time; also,  the  erythrocyte receptor-modifying activity of an 
adenovirus  suspension  remained  functionally unchanged following repeated 
reactions with red cells, whereas the erythrocytes were rendered inagglutinable 
for test virus hemagglutinin. However, definitive proof of an enzyme-substrate 
reaction will require  further evidence, such as the demonstration of reaction 
products formed as the result of the reaction. 
Although  erythrocyte receptors  for  the  adenovirus  hemagglutinins  were 
abolished by treatment with the RDE of Vibrio cholerae and markedly reduced 
after treatment with influenza types A and B (6), the mechanism of action of 
the adenovirus factor did not appear to be identical to that of neuraminidase. 
This lack of similarity is indicated by the findings that the adenovirus  factor 
did not alter the agglutination capacity of erythrocytes for myxovirus hemag- 
glutinins,  and that adenovirus  type 1 and 2 suspensions were devoid of neura- 
minidase activity (14) in assays done by the method of Warren (15). A further 
difference from the activity of RI)E is the fact that Vibrio cholerae and influ- 
enza enzymes destroyed the receptors of human red cells for adenovirus  types 
8 and 9, whereas, the adenovirus  erythrocyte-modifying  factor did not affect 
the receptors for types 8 and 9. 
The functional significance, if any, of the erythrocyte receptor  modifying- 
factor in adenovirus infection needs further definition. 
SUMTMARY 
Agglutinability of human erythrocytes for 3 hemagglutinating adenoviruses 
was markedly reduced  by pretreatment of red cells with a factor present in 
tissue cultures which had been infected with adenovims types 1, 2, 4, or 15. 
The  factor  responsible  for  erythrocyte  receptor  modification  was  non- 728  ERYTHROCYTE  RECEPTOR--MODIFYING  FACTOR 
dialyzable and unaffected by the  action  of ribonuclease,  desoxyribonuclease, 
trypsin,  chymotrypsin, or ether. The factor was  smaller,  more thermostable, 
and separable from the infectious virus. 
Erythrocyte receptor modification was found to be a  function of time and 
temperature.  Titers of erythrocyte receptor-modifying activity were not  di- 
minished by successive exposures to fresh erythrocytes. Erythrocytes treated 
with erythrocyte receptor-modifying factor suspensions failed to significantly 
adsorb test virus hemagglutinin. 
Inhibition  of  erythrocyte receptor  modifying-activity  of  the  adenovirus 
suspensions by rabbit antiserum was type-specific. 
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